Pharsight

Angiomax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7598343 SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jul, 2028

(4 years from now)

US7582727 SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jul, 2028

(4 years from now)

US7582727

(Pediatric)

SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jan, 2029

(5 years from now)

US7598343

(Pediatric)

SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jan, 2029

(5 years from now)

Angiomax is owned by Sandoz Inc.

Angiomax contains Bivalirudin.

Angiomax has a total of 4 drug patents out of which 0 drug patents have expired.

Angiomax was authorised for market use on 15 December, 2000.

Angiomax is available in injectable;intravenous dosage forms.

The generics of Angiomax are possible to be released after 27 January, 2029.

Drugs and Companies using BIVALIRUDIN ingredient

Market Authorisation Date: 15 December, 2000

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ANGIOMAX before it's drug patent expiration?
More Information on Dosage

ANGIOMAX family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic